“Early detection of Cytokine Release Syndrome (CRS) using digital health products and predictive algorithms will enable us to maximize the potential of cell therapies and T-cell engagers.

The collaboration with DATAcc by DiMe has been instrumental in supporting the industry towards this objective. I am optimistic about a future where more patients will have access to and benefit from these transformative therapies.”

– Premal Kamdar | Director, Digital Health Product Management, Bristol Myers Squibb